New program aims to cut hospital visits by helping cancer patients speak up

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must have a diagnosis of a solid tumor malignancy of any stage * Participants must be identified as high risk, defined as having 6 month mortality estimate from machine learning (ML) algorithm \>= 20% * Participants must not be receiving or have pre-existing plans to enter hospice care at the time of study registration * Participant must be actively receiving or planning to receive systemic anti-cancer therapy (defined as any oral, injection, or intravenous therapy against cancer) within 3 months after registration * NOTE: This includes chemotherapy (conventional or cytotoxic chemotherapy), hormone therapy, targeted therapy, and immunotherapy * NOTE: Participants are allowed to be co-enrolled on other clinical trials including trials using investigational agents * Participants must be \>= 18 years of age at the time of study enrollment * Participants who can complete Patient Reported Outcome (PRO) questionnaires in English or Spanish must be willing to 1) complete PROs at all scheduled assessments; and 2) complete the pre-registration (baseline) PRO forms within 14 days prior to registration * Participants must be able to provide a valid telephone number for the purpose of being contacted by the lay health worker * NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system * Patient and clinician participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. This protocol does not permit use of Legally Authorized Representative NOTE: For this study, in the OPEN registration, clinician participants will be listed as their own treating investigator. However, clinician participants must not consent themselves or sign their own eligibility criteria forms